ACT MALI: Treatment of Malaria Based on Combination Therapies

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Artemisinins; Artesunate; Fanasil, pyrimethamine drug combination; Lumefantrine; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Body weight > 5kg

• Residence in the investigator site area for the duration of the trial

• Axillary temperature ≥ 37,5°C at Day 0

• Confirmed Plasmodium falciparum infection,with parasitemia range from 2000 to 200000 asexual parasites /µl of blood

Exclusion Criteria:

• Danger signs or signs of severe malaria

• Other severe illnesses

• Allergy to one of the drugs

• Pregnant women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.